Vertex Pharmaceuticals (VRTX) Intangibles (2009 - 2026)

Vertex Pharmaceuticals has reported Intangibles for 18 years, with the latest figure at $418.5 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 5.15% year-over-year to $418.5 million; the trailing twelve-month figure through Mar 2026 stood at $418.5 million (down 5.15% YoY), and the FY2025 full-year result was $424.2 million, down 48.64% from the prior year.
• Intangibles for Q1 2026 stood at $418.5 million, down from $424.2 million in the prior quarter.
• The five-year high for Intangibles was $839.9 million in Q4 2023, with the low at $387.0 million in Q2 2022.
• Average Intangibles over 5 years is $595.5 million, with a median of $603.6 million recorded in 2022.
• Year-over-year, Intangibles soared 55.97% in 2023 and slumped 48.64% in 2025.
• Tracing VRTX's Intangibles over 5 years: stood at $603.6 million in 2022, then surged by 39.15% to $839.9 million in 2023, then decreased by 1.67% to $825.9 million in 2024, then tumbled by 48.64% to $424.2 million in 2025, then decreased by 1.34% to $418.5 million in 2026.
• The last three Intangibles figures came in at $418.5 million (Q1 2026), $424.2 million (Q4 2025), and $429.8 million (Q3 2025), per Business Quant data.

Peer Comparison